THE DAY, IN CONTEXTPolaris InsightsAn AI-powered comprehensive news portal

POLARIS INSIGHTS

Adma Biologics reiterates at least $530M 2026 revenue and raises minimum adjusted EBITDA to at least $275M as ASCENIV demand accelerates

The development centers on adma Biologics reiterates at least $530M 2026 revenue and raises minimum adjusted EBITDA.

Read the full account of the story

More from the Markets desk

More from Markets · Back to Polaris Insights